Crispr Therapeutics AG (CRSP) Receives a Hold from RBC Capital

RBC Capital maintained a Hold rating on Crispr Therapeutics (CRSP) with a $50 target. UBS also gave a Hold, while Piper Sandler reiterated a Buy. CRSP reported Q2 revenue of $10.18M and a net loss of $91.15M. Insider sentiment is negative, with recent sales by directors.

Original reporting
Published Nov 5, 2026, 4:57 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 6:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Crispr Therapeutics AG (CRSP) Receives a Hold from RBC Capital — source image
Decision brief

The 30-second read

$CRSPBearishLow
01

Why it matters

Analyst holds and insider sales suggest limited upside, but the earnings improvement may soften negative pressure.

02

Market read

The article provides modest new information—analyst holds and insider sales—offering limited actionable insight for traders.

03

What to watch

Potential upcoming clinical trial data or partnership announcements not covered in the article.

Relevance 4/10Novelty 2/10Timing: today

Background

CRISPR Therapeutics reported Q2 revenue of $10.18 million and a GAAP loss of $91.15 million, a significant improvement from the prior year.

Company-level read

Ticker impact

$CRSPBearishMedium confidence
Context

RBC Capital and UBS maintain Hold ratings with a $50 price target; Piper Sandler reiterates Buy; recent insider sales of 13,679 shares for $780,934.

Expected impact

likely pressure as the market prices in the hold rating and insider sell activity

Evidence & confidence

Hold ratings provide no catalyst, while insider selling signals reduced confidence, which may weigh on the stock.

Market effects

Minimal impact on the broader biotech sector; similar companies may see modest sentiment drift.

No significant regional effect; news is confined to U.S. investors.

Low global relevance; limited to CRSP shareholders.

Counterpoint

Despite the hold ratings, the recent earnings beat and revenue growth could support a short‑term rally.

Key entities

  • Luca Issi

    RBC Capital analyst who maintained a Hold rating with a $50 target.

  • Joon Lee

    UBS analyst who also maintained a Hold rating.

  • Ali Behbahani

    CRSP director who sold 13,679 shares.

Related articles

$CRSPMed

Seawolf Therapeutics San Diego $100M Sanofi DNA Deal

Seawolf Therapeutics, a San Diego biotech, raised $100M and partnered with Sanofi for a deal potentially worth $1.2B. The company's TRIDENT platform aims to enable repeat dosing of gene therapies. Seawolf's lead program targets metabolic diseases, with human trials expected by 2028. Investors include Eli Lilly, Novartis Venture Fund, and CRISPR Therapeutics.

$CRSPHighAI 8/10

Piper Sandler reiterates CRISPR Therapeutics stock rating at overweight

Piper Sandler maintained an Overweight rating and $110 price target for CRISPR Therapeutics (CRSP) after positive clinical data presentations. CTX310 showed significant reductions in lipid parameters, while zugo-cel demonstrated high response rates in various diseases. CRSP reported Q3 2026 sales of $99M for CASGEVY and holds $2.36B in cash. Analysts have mixed views on its valuation and price targets.

$CRSPMedAI 8/10

CRISPR Therapeutics reports trial results for gene therapy CTX310

CRISPR Therapeutics (CRSP) reported Phase 1b trial results for CTX310, a gene therapy for severe hypertriglyceridemia. The trial showed significant reductions in triglycerides, ANGPTL3 protein, and other cholesterol markers. No serious adverse events were reported. The FDA has granted RMAT designations to CTX310 for this indication and for elevated LDL cholesterol.